Clinical trial
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With…
NCT05198934 · Amgen, Industry · Active, not recruiting
Key facts
| NCT number | NCT05198934 |
|---|---|
| Title | Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation |
| Official title | A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation |
| Acronym | CodeBreak300 |
| Lead sponsor | Amgen, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer (CRC) |
| Intervention type | Drug |
| Interventions | Sotorasib, Panitumumab, Trifluridine and Tipiracil, Regorafenib |
| Enrollment | 160 |
| Start date | Apr 19, 2022 |
| Primary completion | Jul 16, 2025 |
| Completion | May 14, 2026 |
| First posted | Jan 20, 2022 |
| Last update posted | Feb 6, 2026 |
| Countries | Australia, France, Germany, Greece, Italy, Japan, Mexico, South Korea, Spain, Taiwan, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: